SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust is experiencing heightened volatility as investors react to presidential commentary on the ongoing conflict in Iran, with market participants closely monitoring the potential for a prolonged ground offensive. The community remains deeply divided, with many traders expressing skepticism regarding market rallies driven by policy announcements while others debate the long-term economic implications of energy security and geopolitical escalation.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

Markets are pulling back amid heightened geopolitical anxiety following a recent speech by President Trump regarding the ongoing Iran conflict, leading investors to re-evaluate their exposure as oil prices surge toward new highs. The community is actively debating the potential for long-term economic instability and energy-driven inflation, with many traders questioning the market's reliance on policy-driven headlines and rotating out of riskier assets ahead of the long weekend.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as investors digest a mix of geopolitical volatility and high-stakes capital expansion, with ongoing discussions focusing on the company's $2 billion investment in Marvell Technology and its central role in the hyperscaler AI buildout. Market sentiment remains polarized as traders weigh the impact of export policies and supply chain constraints against the company's massive revenue growth and role as the primary engine of the AI infrastructure boom.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as its community builds consistent momentum and excitement ahead of the 4/20 holiday, with participants emphasizing the project's long-term cultural mission and organic growth. The community actively discusses the coin's role in the global cannabis movement and remains focused on building a solid, steady environment that distinguishes it from more volatile, short-term trends.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors weigh significant long-term growth potential in server CPUs and AI infrastructure against short-term volatility driven by geopolitical instability in the Middle East. The community remains divided, with many debating the impact of chip supply chain constraints and fab capacity against optimistic institutional price targets and technical consolidation at key support levels.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the public react to the President's latest speech on the Iran conflict, fueling intense discourse around market volatility, geopolitical instability, and concerns regarding his administrative performance. Community members are actively debating the potential for an imminent military escalation, the impact on global oil markets, and broader criticisms of his leadership style.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is facing intense market scrutiny as investors weigh its aggressive $9 billion pursuit of Globalstar against broader geopolitical risks, including recent reports of infrastructure damage in Bahrain and rising energy costs. The community is deeply divided between long-term bulls accumulating shares at current price levels and short-term traders reacting to volatility, with much of the conversation centered on the high-stakes negotiation with Apple and the company's ability to compete with SpaceX's Starlink.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is currently a focal point for investors as the semiconductor sector navigates supply chain constraints and semiconductor foundry bottlenecks, with market participants closely monitoring its role as a key infrastructure provider for AI. While some traders are executing tactical liquidations to capture potential volatility, community sentiment remains split between those cautious of broader geopolitical risks and those viewing recent pullbacks as a strategic opportunity to accumulate shares in a long-term AI leader.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSMC is trending as the central pillar of the global AI supply chain, with institutional investors showing sustained confidence in its foundry leadership despite ongoing geopolitical and supply chain risks. The community is actively discussing the stock's massive capacity demand, with advanced nodes effectively booked through 2028, and monitoring the balance between its critical role in the hardware ecosystem and macro-level market volatility.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is surging as investors closely monitor escalating geopolitical tensions in the Middle East and their impact on global energy supplies, with the community highlighting a massive revenue surge and potential short-squeeze dynamics driven by high borrow fees. While bullish traders are focused on the company's strategic position in natural gas and the potential for explosive price action, others remain cautious of high volatility and broader market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The investigational therapy was granted Rare Pediatric Disease designation for the treatment of DMD in December and an Orphan Drug Designation in January.&nbsp;</li><li>The company reported net loss per share of $4.04 for 2025, compared to a loss of $3.04 in 2024, and above an analyst estimate of a loss of $3.91.</li><li>Last month, Atossa said that the company will not proceed with advancing its drug in metastatic breast cancer.</li></ul>Shares of Atossa Therapeutics (ATOS) slipped 4% after hours on Wednesday after the company said that it continues to align its resources towards potential commercialization of (Z)-endoxifen after it reported a wider full year loss.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.atossatherapeutics.com/2026-03-25-Atossa-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provides-a-Corporate-Update">said</a> that it is working to advance its experimental drug (Z)-endoxifen in certain rare disease indications such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) in addition to breast cancer. The investigational therapy was granted Rare Pediatric Disease designation for the treatment of DMD in December and an Orphan Drug Designation in January.“We believe these FDA designations are important for future development as they both help to speed the FDA review process as well as provide potential financial benefits in the future," CEO Steven Quay said on Wednesday.Last month, Atossa said that the company will not proceed with advancing its drug in metastatic breast cancer due to the overall cost and timeline required to conduct later-stage studies in the indication. The company then said it will prioritize its resources on other oncology and rare disease areas with “higher potential returns on investments.”<h2 class="st-heading-2">Q4 Earnings</h2>The company said on Wednesday that its operating expenses rose in 2025 to $37.1 million, compared to $9.5 million in 2024, owing to a significant rise in research and development expenses for (Z)-endoxifen.The company reported net loss per share of $4.04 for 2025, compared to a loss of $3.04 in 2024, and above an analyst estimate of a loss of $3.91. The company ended the year with cash and cash equivalents of $41.29 million, compared to $71.08 million as of 2024-end.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ATOS stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<a href="https://stocktwits.com/symbol/ATOS">ATOS stock</a> has dropped 50% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/wkhs-stock-rallies-after-hours-on-unveiling-cheaper-electric-delivery-van/cZ3pPW4RIjI">WKHS Stock Rallies After Hours On Unveiling Cheaper Electric Delivery Van</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Atossa Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug

The company said that it is working to advance its experimental drug (Z)-endoxifen in certain rare disease indications such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) in addition to breast cancer.

Equity

The company said that it is working to advance its experimental drug (Z)-endoxifen in certain rare disease indications such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) in addition to breast cancer.


Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and...

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two...

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference Atossa Therapeutics Presents Clinical Trial Update Highlighting...

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026...

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program Atossa Therapeutics Maintains Strong...

Atossa Genetics (NASDAQ:ATOS) Sees Large Volume Increase - What's Next?

Atossa Genetics (NASDAQ:ATOS) Sees Large Volume Increase - Still a Buy...

<ul class="summary-bullets"><li>Each of 15 shares of the company’s common stock outstanding was combined into one new share of common stock.</li><li>No fractional shares were issued as a result of the split.&nbsp;</li><li>In January, the FDA granted Orphan Drug Designation to Atossa’s (Z)-endoxifen for the treatment of Duchenne muscular dystrophy.</li></ul>Shares of Atossa Therapeutics Inc. (ATOS) fell a steep 32% on Monday after the stock began trading on a split adjusted basis at trade open.Atossa <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001488039/000119312526021727/atos-20260120.htm">said</a> last week that its Board of Directors has approved a reverse stock split of the company’s common stock, at a ratio of 15:1, with an effective time of 12:01 a.m. Eastern Time on February 2, 2026.Each of 15 shares of the company’s common stock outstanding was combined into one new share that started trading on a split-adjusted basis on Monday. No fractional shares were issued as a result of the split.<h2 class="st-heading-2">New Designations</h2>In January, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Atossa’s (Z)-endoxifen for the treatment of Duchenne muscular dystrophy. The drug was previously granted Rare Pediatric Disease designation for the treatment of DMD as well.Duchenne muscular dystrophy is a severe, progressive, X-linked genetic disorder, primarily affecting boys, characterized by the lack of the protein dystrophin, leading to muscle degeneration.The orphan drug designation is granted to therapies intended to treat rare diseases and offers incentives such as regulatory support. The drug is yet to be approved for any indication. However, the FDA gave clearances for studying the drug in metastatic breast cancer earlier in January.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ATOS stock stayed within the ‘bullish’ territory, while message volume remained at ‘high’ levels.A Stocktwits user highlighted concerns about a potential dilution. The company has cash and cash equivalents of $51.8 million as of September end. &nbsp;<stembedurl>https://www.stocktwits.com/St0ckt0k101/message/643702353</stembedurl>Another said that they are “relieved” the company didn’t get delisted.<stembedurl>https://www.stocktwits.com/RealTurd/message/643701100</stembedurl><a href="https://stocktwits.com/symbol/ATOS">ATOS stock</a> has lost 54% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-seemingly-confirms-xai-spacex-merger-talks/cZbgtmrR4kZ">Elon Musk Seemingly Confirms xAI-SpaceX Merger Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ATOS Stock Tumbles 32% — Here’s What Retail Investors Think Of The Reverse Stock Split

Atossa Therapeutics said last week that its board has approved a reverse stock split of the company’s common stock, at a ratio of 15:1, with an effective time of 12:01 a.m. Eastern Time on February 2, 2026. 

Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 56.4% in January

Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 3,621,023...

Atossa Genetics (NASDAQ:ATOS) Shares Set to Reverse Split on Monday, February 2nd

Atossa Genetics Inc. (NASDAQ:ATOS - Free Report) shares are going to reverse split on the morning of Monday, February 2nd. The 1-15 reverse split was announced on Monday, January 26th. The number of...

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Atossa Therapeutics Inc

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Current Price	$5.11
Prev Close	$5.26
Open	$5.27
Dividend Yield	0.00%
50-Day Moving Average	$5.56
Beta	1.34
Avg. Volume	85,508.98
PE Ratio	-1.27

52-Week High	$19.35
52-Week Low	$3.76
Market Capitalization	$45.3M
EPS (Annual)	-$4.04
Price to Book	1.12
Revenue Per Employee	$0.00

ATOS
Atossa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATOS News

ATOSAtossa Therapeutics Inc